Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM
JACC · 2026-02 · 87 (5) · 490-501
DOI: 10.1016/j.jacc.2025.09.013 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC, 2026-02. Verfasst von Ahmad Masri und 21 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health and Science University, Portland, Oregon, USA. Electronic address: masria@ohsu.edu. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Cardiovascular Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a progressive disease with a significant burden of recurrent cardiovascular (CV) events. Acoramidis, an approved oral therapy for ATTR-CM, achieves early, near-complete (≥90%) TTR stabilization. In the phase 3 ATTRibute-CM (Efficacy and Safety of Acoramidis in Participants with Transthyretin Amyloid Cardiomyopathy) study, acoramidis significantly reduced the composite of all-cause mortality or first CV-related hospitalization (CVH), with an effect observed at month 3. Its efficacy on the burden of cumulative CV outcome events has not been reported. OBJECTIVES: This study was a post hoc exploratory recurrent-event analysis of the efficacy of acoramidis on the cumulative incidence of CV outcomes from ATTRibute-CM and its open-label extension. METHODS: Cumulative incidences of centrally adjudicated CV-related mortality (CVM) or recurrent CVH (first and, if applicable, subsequent CVH), recurrent CVH alone (month 30), and CVM (month 42) were measured in the modified intention-to-treat population (acoramidis, n = 409; placebo, n = 202). Mean cumulative events by treatment, and the difference between treatment groups were estimated by using a modified Andersen-Gill model. RESULTS: Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through month 30 vs placebo (HR: 0.51; 95% CI: 0.43-0.62; P < 0.0001). A notable proportion of CV outcome events (19% of CVM or recurrent CVH events, 22% of CVH) occurred within the first 6 months. Numerically fewer cumulative events were observed with acoramidis compared with placebo at month 1, and the difference increased progressively, resulting at month 30 in 53 events avoided per 100 treated participants (95% CI: 29-79). At month 42, CVM was reduced with continuous acoramidis vs placebo-to-acoramidis (HR: 0.55; 95% CI: 0.39-0.79; P = 0.0011). The annualized frequency of recurrent CVH was significantly decreased through month 30 (relative risk ratio: 0.50; 95% CI: 0.35-0.69; P < 0.0001). CONCLUSIONS: Acoramidis significantly reduced the cumulative burden of CV outcomes in ATTR-CM over 30 months. Numerically fewer events were observed with acoramidis vs placebo by month 1, and the difference increased progressively over time, resulting in 53 events avoided per 100 treated patients at month 30. Almost one-fourth of the cumulative CV events occurred within the first 6 months. These exploratory findings suggest that cumulative event burden may occur early, highlighting the importance of timely evaluation, diagnosis and treatment in ATTR-CM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oregon Health and Science University, Portland, Oregon, USA. Electronic address: masria@ohsu.edu.
- Medical University of South Carolina, Charleston, South Carolina, USA.
- Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, Massachusetts, USA.
- National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.
- Parkland Health and Hospital System, Dallas, Texas, USA; University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Amyloidosis Research and Treatment Center, Pavia, Italy.
Zitieren
APA
Masri, A., Judge, D. P., Ruberg, F. L., Gillmore, J. D., Grodin, J. L., Obici, L., Maurer, M. S., Fontana, M., Poulsen, S. H., van der Meer, P., Cheng, R. K., Cuddy, S. A. M., Ambardekar, A. V., Xiong, K., Cao, X., Murtagh, G., Siddhanti, S., Castaño, A., Tamby, J. F., …, & Witteles, R. (2026). Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM. JACC, 87(5), 490-501. https://doi.org/10.1016/j.jacc.2025.09.013
Vancouver
Masri A, Judge DP, Ruberg FL, Gillmore JD, Grodin JL, Obici L, et al. Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM. JACC. 2026;87(5):490-501. doi:10.1016/j.jacc.2025.09.013
BibTeX
@article{Masri2026,
author = {Masri, Ahmad and Judge, Daniel P and Ruberg, Frederick L and Gillmore, Julian D and Grodin, Justin L and Obici, Laura and Maurer, Mathew S and Fontana, Marianna and Poulsen, Steen Hvitfeldt and van der Meer, Peter and Cheng, Richard K and Cuddy, Sarah A M and Ambardekar, Amrut V and Xiong, Kuangnan and Cao, Xiaofan and Murtagh, Gillian and Siddhanti, Suresh and Castaño, Adam and Tamby, Jean-François and Fox, Jonathan C and Alexander, Kevin M and Witteles, Ronald},
title = {Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM},
journal = {JACC},
year = {2026},
volume = {87},
number = {5},
pages = {490--501},
doi = {10.1016/j.jacc.2025.09.013}
}
EUVIMED